Home LiteratureArticle Details
PMID: 14710231 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer.

British journal of cancer ·Vol. 90 ·No. 1 ·2004-01-12 ·Pages 206-15

Fondevila C, Metges JP, Fuster J, Grau JJ, Palacín A, Castells A, Volant A, Pera M

Abstract

This study was undertaken to determine the value of tumour microvessel density (MVD) and the expression of p53 and vascular endothelial growth factor (VEGF) as prognostic markers in patients with gastric cancer operated on for cure. In all, 156 patients with curatively resected gastric cancer constituted the basis of this blinded retrospective evaluation. Patients were treated with either surgery alone (n=53) or surgery plus adjuvant chemotherapy (n=103). Tumour MVD, p53 expression, and VEGF expression were assayed using immunohistochemical techniques. After a mean follow-up of 43 months, 64 (41%) patients had died and 55 (35%) patients developed tumour recurrence. Positive correlations between MVD and both p53 (P=0.005) and VEGF (P=0.005) expression were observed. Both MVD >/=100 (P=0.05) and positive VEGF expression (P<0.02) were associated with shorter disease-free survival, and positive VEGF expression (P=0.01) was also associated with shorter overall survival. Multivariate analysis confirmed that, in addition to the pathological tumour stage, lymph node ratio, the extent of lymphadenectomy and perineural invasion, p53 expression, and VEGF expression were independently associated with both disease-free survival (P<0.0005 and 0.02, respectively) and overall survival (P<0.02 and 0.01, respectively). Finally, patients whose tumours did not show p53 expression had a survival benefit compared to those expressing p53 when treated with adjuvant chemotherapy (P=0.01). This investigation demonstrates that p53 expression and VEGF expression are independent prognostic factors for both disease-free survival and overall survival in patients with curatively resected gastric cancer, and that p53 status may also influence response to chemotherapy.

MeSH Terms
Adult Aged Aged, 80 and over Chemotherapy, Adjuvant Disease-Free Survival Female Humans Male Middle Aged Neoplasm Recurrence, Local Predictive Value of Tests Prognosis Retrospective Studies Stomach Neoplasms/genetics,pathology,surgery Tumor Suppressor Protein p53/biosynthesis Vascular Endothelial Growth Factor A/biosynthesis
Chemicals
Tumor Suppressor Protein p53 Vascular Endothelial Growth Factor A
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Fondevila C
Services of Gastrointestinal Surgery, Institut de Malalties Digestives, Hospital Clínic, Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), University of Barcelona Medical School, Barcelona, Spain.
Metges J P
Fuster J
Grau J J
Palacín A
Castells A
Volant A
Pera M
References (53)
53 references, click to expand
  1. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials.
    Eur J Cancer. 1999 Jul;35(7):1059-64 PMID: 10533448
  2. Randomized trial of adjuvant chemotherapy with mitomycin plus ftorafur versus mitomycin alone in resected locally advanced gastric cancer.
    J Clin Oncol. 1998 Mar;16(3):1036-9 PMID: 9508188
  3. The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: Fifth Edition American Joint Committee on Cancer staging, proximal disease, and the "different disease" hypothesis.
    Cancer. 2000 Feb 15;88(4):921-32 PMID: 10679663
  4. Angiogenesis inhibitor, TNP-470, suppresses growth of peritoneal disseminating foci.
    Hepatogastroenterology. 2000 Jan-Feb;47(31):298-302 PMID: 10690624
  5. Overexpression of the heat shock protein HSP70 family and p53 protein and prognosis for patients with gastric cancer.
    Oncology. 2000 Feb;58(2):144-51 PMID: 10705241
  6. Vascular invasion and potential for tumor angiogenesis and metastasis in gastric carcinoma.
    Surgery. 2000 Sep;128(3):408-16 PMID: 10965312
  7. Angiogenic interactions of vascular endothelial growth factor, of thymidine phosphorylase, and of p53 protein expression in locally advanced gastric cancer.
    Oncol Res. 2000;12(1):33-41 PMID: 11061344
  8. Gastric cancer recurrence: clues for future approaches to avoiding an old problem.
    J Clin Gastroenterol. 2001 Jan;32(1):3-4 PMID: 11154165
  9. P53 protein expression in gastric adenocarcinoma. Negative predictor of survival after postoperative adjuvant chemotherapy.
    Anticancer Res. 2000 Sep-Oct;20(5C):3929-33 PMID: 11268479
  10. Cancer statistics, 2001.
    CA Cancer J Clin. 2001 Jan-Feb;51(1):15-36 PMID: 11577478
  11. Relationship between the expression of iNOS,VEGF,tumor angiogenesis and gastric cancer.
    World J Gastroenterol. 2002 Aug;8(4):591-5 PMID: 12174362
  12. TP53 and gastric carcinoma: a review.
    Hum Mutat. 2003 Mar;21(3):258-70 PMID: 12619111
  13. The prognostic significance of microvessel density and thymidine phosphorylase expression in squamous cell carcinoma of the esophagus.
    Cancer. 1998 Apr 1;82(7):1225-32 PMID: 9529012
  14. Relationship of p53 and vascular endothelial growth factor expression of clinicopathological factors in human scirrhous gastric cancer.
    Eur Surg Res. 1998;30(2):130-7 PMID: 9565747
  15. Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum.
    Clin Cancer Res. 1998 Jun;4(6):1469-74 PMID: 9626464
  16. Association between tumor angiogenesis and Borrmann type 4 carcinomas of the stomach.
    Oncology. 1998 Sep-Oct;55(5):461-7 PMID: 9732226
  17. Tumor angiogenesis and micrometastasis in bone marrow of patients with early gastric cancer.
    Clin Cancer Res. 1998 Sep;4(9):2129-34 PMID: 9748130
  18. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy.
    Cancer Metastasis Rev. 1998 Jun;17(2):155-61 PMID: 9770111
  19. Expression of p53 and vascular endothelial growth factor associated with tumor angiogenesis and prognosis in gastric cancer.
    Oncology. 1998 Nov-Dec;55(6):594-9 PMID: 9778629
  20. Expression of p53 protein and resistance to preoperative chemotherapy in locally advanced gastric carcinoma.
    Cancer. 1998 Nov 1;83(9):1917-22 PMID: 9806649
  21. Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer.
    Clin Cancer Res. 1996 Oct;2(10):1679-84 PMID: 9816116
  22. Angiogenesis as an unfavorable factor related to lymph node metastasis in early gastric cancer.
    Ann Surg Oncol. 1998 Oct-Nov;5(7):585-9 PMID: 9831105
  23. p53 immunoreactivity and single-strand conformational polymorphism analysis often fail to predict p53 mutational status.
    Mod Pathol. 1999 Jan;12(1):54-60 PMID: 9950163
  24. Estimates of the worldwide incidence of 25 major cancers in 1990.
    Int J Cancer. 1999 Mar 15;80(6):827-41 PMID: 10074914
  25. Prognostic value of p53 protein expression for patients with gastric cancer--a multivariate analysis.
    Br J Cancer. 1999 Mar;79(7-8):1255-61 PMID: 10098768
  26. The role of vascular endothelial growth factor (VEGF) and p53 status for angiogenesis in gastric cancer.
    Korean J Intern Med. 2002 Dec;17(4):211-9 PMID: 12647634
  27. Cyclooxygenase-2 overexpression correlates with vascular endothelial growth factor expression and tumor angiogenesis in gastric cancer.
    J Clin Gastroenterol. 2003 Jul;37(1):28-33 PMID: 12811205
  28. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53.
    Science. 1992 Jan 24;255(5043):459-62 PMID: 1346476
  29. Gastric cancer with p53 overexpression has high potential for metastasising to lymph nodes.
    Br J Cancer. 1993 Mar;67(3):589-93 PMID: 8439509
  30. p53 mutation in gastric cancer: a genetic model for carcinogenesis is common to gastric and colorectal cancer.
    Int J Cancer. 1993 Jul 9;54(5):759-64 PMID: 8392033
  31. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials.
    J Clin Oncol. 1993 Aug;11(8):1441-7 PMID: 8336183
  32. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents.
    Cell. 1993 Sep 24;74(6):957-67 PMID: 8402885
  33. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression.
    Oncogene. 1994 Mar;9(3):963-9 PMID: 8108142
  34. The prognostic significance of the accumulation of p53 tumour-suppressor gene protein in gastric adenocarcinoma.
    Br J Cancer. 1994 May;69(5):943-6 PMID: 8180028
  35. p53 status and the efficacy of cancer therapy in vivo.
    Science. 1994 Nov 4;266(5186):807-10 PMID: 7973635
  36. Tumor angiogenesis as a predictor of recurrence in gastric carcinoma.
    J Clin Oncol. 1995 Feb;13(2):477-81 PMID: 7531224
  37. The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents.
    Int J Cancer. 1995 Feb 20;64(1):37-46 PMID: 7665247
  38. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression.
    Cancer Res. 1995 Dec 15;55(24):6161-5 PMID: 8521408
  39. p53 mutations in the non-neoplastic mucosa of the human stomach showing intestinal metaplasia.
    Int J Cancer. 1996 Feb 20;69(1):28-33 PMID: 8600055
  40. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma.
    Cancer. 1996 Mar 1;77(5):858-63 PMID: 8608475
  41. Extent of tumor vascularization correlates with prognosis and hematogenous metastasis in gastric carcinomas.
    Cancer Res. 1996 Jun 1;56(11):2671-6 PMID: 8653715
  42. The relationship of p53 expression to the prognosis of 418 patients with gastric carcinoma.
    Cancer. 1995 Sep 1;76(5):720-6 PMID: 8625172
  43. Expression of p53 protein as a prognostic factor in patients with gastric cancer.
    Eur J Cancer. 1996 Feb;32A(2):215-20 PMID: 8664030
  44. Strategies to decrease the incidence of intra-abdominal recurrence in resectable gastric cancer.
    Br J Surg. 1996 Jun;83(6):726-33 PMID: 8696727
  45. Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma. Association with angiogenesis and tumor progression.
    Cancer. 1997 Jan 15;79(2):206-13 PMID: 9010092
  46. Correlation between expression of vascular endothelial growth factor and tumor vascularity, and patient outcome in human gastric carcinoma.
    J Clin Oncol. 1997 Feb;15(2):826-32 PMID: 9053510
  47. Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation.
    Eur J Cancer. 1996 Dec;32A(14):2474-84 PMID: 9059336
  48. Relationship between p53 overexpression and gastric cancer progression.
    Oncology. 1997 Mar-Apr;54(2):166-70 PMID: 9075790
  49. Antiangiogenesis for cancer therapy.
    Lancet. 1997 May;349 Suppl 2:SII13-5 PMID: 9164441
  50. Effect of angiogenesis inhibitor TNP-470 on the progression of human gastric cancer xenotransplanted into nude mice.
    Int J Cancer. 1997 May 29;71(5):838-41 PMID: 9180154
  51. TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer.
    Cancer. 1997 Nov 1;80(9):1803-4 PMID: 9351551
  52. p53 expression in gastric cancer: clinicopathological correlation and prognostic significance.
    Dig Dis Sci. 1997 Dec;42(12):2463-7 PMID: 9440620
  53. Recurrence following curative resection for gastric carcinoma.
    Br J Surg. 2000 Feb;87(2):236-42 PMID: 10671934
Article Info
Journal
British journal of cancer
Abbr.
Br J Cancer
ISSN
0007-0920
Published
2004-01-12
Pages
206-15
Language
English
Region
England
NLM ID
0370635
PMCID
PMC2395306
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com